CRC tissues; matched adjacent non-cancer tissues; adjacent non-tumour tissues; lung
SW480; SW620; RKO; DLD-1; HCT116; HT-29; 293T; FHC
cell line-derived xenograft
proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); apoptosis (promotes); ceRNA regulation (promotes); Hippo/YAP (inhibits); mRNA stability (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; ISH (In Situ Hybridization); Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Annexin V/PI Flow Cytometry; Transwell Assay; In Vivo Animal Model; H&E Staining; Western Blot; Co-IP; Cohort Study; Survival Analysis; Bioinformatics Analysis
High circ-LECRC expression correlated with lower TNM stage and favourable survival prognosis, while low expression correlated with more aggressive disease and poor prognosis.
Circ-LECRC is a YAP1-derived circRNA that is downregulated in colorectal cancer and acts as a tumor suppressor. It sponges miR-135b-5p to increase KLF4 expression, thereby inhibiting oncogenic YAP1 signalling and reducing proliferation, migration, invasion, tumorigenicity, and lung metastasis while promoting apoptosis. Clinically, higher circ-LECRC expression is associated with lower TNM stage and better survival prognosis.
0.887
YAP derived circ-LECRC functions as a "brake signal" to suppress hyperactivation of oncogenic YAP signalling in colorectal cancer.
combined biological and clinical study